

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Breast cancer	ADP-ribosylation factor 1 (ARF1)	<p>Mouse studies identified an ARF1 inhibitor that could help treat breast cancer. A computational method identified AMF-26 as an ARF1 inhibitor that was structurally distinct from brefeldin A, which has poor oral bioavailability. In a mouse xenograft model of breast cancer, oral treatment with AMF-26 induced tumor regression compared with vehicle treatment. Next steps could include testing AMF-26 in mouse models of other cancer types.</p> <p>SciBX 5(3); doi:10.1038/scibx.2012.64 Published online Jan. 19, 2012</p>	Patent and licensing status unavailable	<p>Ohashi, Y. <i>et al. J. Biol. Chem.</i>; published online Dec. 9, 2011; doi:10.1074/jbc.M111.316125 Contact: Takao Yamori, Japanese Foundation for Cancer Research, Tokyo, Japan e-mail: yamori@jfc.or.jp</p>